Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal Route

Randomized, Two-sequence, Two-treatment, Four-period, Open Label, Single Dose, Crossover, Intravaginal Bioequivalence Study of 200 mg Soft Capsule Progesterone vs Utrogestan® in Healthy Female Subjects Under Fasting Conditions.

This study was designed to assess the bioequivalence of Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine) versus Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France) after a single Vaginal dose in healthy female subjects under fasting conditions.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetics
• Intervention / Treatment: Drug: Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine); Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)

Detailed Description

An open-label, randomized, single dose, two-treatment, four-period, two-sequence, fully replicated crossover bioequivalence study with a washout period of 7 days in healthy female subjects under fasting conditions.Mode of administration:Intravaginally, the capsule introduced deeply into the vagina while lying down.During each period 25 blood samples were drawn 5 mL at (-1.00,-0.50,-0.137), before dosing and at 0.50, 1.00, 1.50, 2.00,2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 9.00, 10.00, 12.00, 16.00, 24.00,36.00, 48.00, and 72.00 hours after dosing.

• Study Type: Interventional
• Enrollment (Actual): 66
• Phase: Phase 1

Contacts and Locations

Study Locations

• Jordan
  • Amman, Jordan, 11910
    • Arab Pharmaceutical Industry Consulting/Pharmaceutical Research Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Non-smoker or past-smoker (an ex-smoker is defined as someone who has completely stopped using nicotine products, including nicotine cessation therapy, for at least 180 days prior to the first study drug administration).
• Body Mass Index (BMI) ≥18.5 and ≤ 30 kg/m2, inclusive and body weight between 45 kg and 100 kg(on the day of screening).
• Subject is available for the whole study and has provided her written informed consent
• Subjects in good health, as determined by screening medical history, physical examination, vital signs assessments (pulse rate, systolic and diastolic blood pressure, and body temperature) and 12-lead electrocardiogram (ECG) . Minor deviations outside the reference ranges will be acceptable, if deemed not clinically significant by the Investigator.
• Acceptance of use of contraceptive measures during the whole study.
• Normal Liver and kidney function tests (on Screening)
• All laboratory screening results within the normal range, or deemed clinically insignificant by Investigator.
• The thickness of the endothelial layer according to ultrasound of the pelvic organs is not less than 2 mm and not more than 4 mm (on Screening)

Exclusion Criteria:

• Known cardiovascular disease, history of hypotension
• History of gout, urolithiasis, nephrolithiasis and hyperuricaemia
• Gastrointestinal diseases, including gastric ulcer, renal or hepatic diseases and/or pathological findings present or in history, which might interfere with the drug pharmacokinetics.
• Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
• Acute or chronic diseases and/or clinical finding which may interfere with the aims of the study or with the drug's safety, tolerability, bioavailability and/or pharmacokinetics of the Investigational Medicinal Product (IMP).
• History of severe allergy or allergic reactions to the study IMP, its excipients or related drugs, wheat allergy history.
• Positive result of urine pregnancy test at screening or breast-feeding or lack of results of pregnancy test.
• Postponed acute diseases of the female genitals during the last 3 months, including vaginitis and / or vulvovaginitis.
• Chronic inflammatory and/or atrophic diseases of the pelvic organs.
• Benign neoplasms and anamnesis of hyperplastic processes, including mastopathy and endometrial hyperplasia.
• Surgical intervention on the pelvic organs, including hysterectomy, adnexectomy (It doesn't include the Subject who had a previous history of Cesarean section for 5 years or more provided that the Cesarean section was not for pathological reasons and/ or accompanied with cervix and uterus diseases or external genitals organs disease).
• Arterial or venous thromboembolism or thrombophlebitis in anamnesis.
• Reporting drug of abuse at screening
• Positive result of alcohol breath test at screening.
• The presence of nicotine or cotinine in urine at the screening.
• Serious mental disease and/or inability to cooperate with clinical team.
• Sitting blood pressure after a minimum of 5 minutes of rest is out of the range of 90-140 mmHg for systolic BP and/or 60-90 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm during the screening procedure.
• Body temperature is out of the range of 35.7-37.6° C at screening.
• Orthostatic hypotension during the screening procedure or in the history.
• Reporting Drug, alcohol (of ≥ 40 g per day pure ethanol), solvents or caffeine abuse at screening.
• Getting a tattoo, body piercing or any cosmetic treatment involving skin piercing within 90 days before the screening unless evaluated by Investigator as non-significant for inclusion in the study.
• Donation of at least 400 ml of blood within 60 days, or more than 150 ml of blood within 30 days, or more than 100 ml blood plasma or platelets within 14 days before study Period I.
• Following a special diet (e.g. vegetarian) or dieting one month before the study initiation
• Allergy on peanut in anamnesis
• Less than 80 days between exit procedure in previous study and the first dosing in this study.
• Any significant clinical abnormality including Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), and / or (human immunodeficiency virus) HIV. (On screening)
• Abnormal Kidney and/or Liver function tests and being assessed as clinically significant by the attending physician. (On screening).
• Results of laboratory tests are outside the normal range and being assessed as clinically significant by the attending physician (On screening).
• Previous liver disease or elevations in serum transaminases alanine aminotransferase (ALT) or aspartate aminotransferase AST ≥1.0 upper limit of normal (ULN) at the screening (ALT for women up to 63 U/L and AST up to 37 U/L).
• Any significant clinical abnormality, including a positive result of HBsAg and/or HCV and/or HIV test during screening procedure.
• Uric acid level for women > 6.0 mg/dl at the screening
• History of kidney disease with impaired renal function and level of creatinine in blood out of the normal laboratory range based on screening
• Anemia, hemoglobin below 12.0 g/L at screening.
• The intake of caffeine, xanthenes, or carbon dioxide (CO2)-containing beverages within 18 hours of drug administration
• Consumption of alcohol, grapefruit or grapefruit containing products within 7 days of drug administration.
• Ingestion of any supplements like vitamins or herbal products within 7 days prior to the initial dose of the study medication.
• Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent significant change in dietary or exercise habits.
• Abnormal Vital Signs and being assessed as clinically significant by the attending physician.
• Vomiting, Diarrhea on admission.
• Use of organ-toxic drugs or systemic drugs known to substantially alter liver metabolism within 90 days before the first dosing.
• Use of any prescription medication for a period of 14 days before the first dosing.
• Any systemic over-the-counter (OTC) drug treatment and/or vitamins and/or herbal treatment and/or food supplements within 14 days before the first dosing.
• Clinically significant illness within 28 days before the first dosing, including major surgery.
• Positive results of drug of abuse at check-in.
• Positive result of alcohol breath test at check-in.
• Reporting Drug, alcohol (of ≥ 40 g per day pure ethanol), solvents or caffeine abuse at check-in
• Positive urine pregnancy test at check-in.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment A; Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine) Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator	Drug: Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine); Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator; Other Names: Injesta
Active Comparator: Treatment B; Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France) Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator	Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France); Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator; Other Names: Utrogestan®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Cmax - Maximum plasma concentration derived/calculated from the concentrations of Progesterone Corrected determined in individual plasma samples for each subject	up to 72 hours post-administration
AUC0→last	AUC0→last -The area under the plasma concentration-time curve	up to 72 hours post-administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tmax	Tmax -The time of the peak concentration	up to 72 hours post-administration
AUC0→inf	Area under the plasma concentration-time curve from 0 h to infinity	up to 72 hours post-administration
λz	λz-Terminal elimination rate constant	up to 72 hours post-administration
Residual area (%)	The residual areas were determined in % by the following equation: {(AUC0→inf - AUC0→last) /AUC0→inf}* 100. The unit is %.	up to 72 hours post-administration
t1/2	t1/2 -The terminal half-life	up to 72 hours post-administration

Collaborators and Investigators

• Sponsor: Joint Stock Company "Farmak"

Study record dates

Study Major Dates

• Study Start (Actual): August 28, 2019
• Primary Completion (Actual): October 21, 2019
• Study Completion (Actual): October 21, 2019

Study Registration Dates

• First Submitted: November 8, 2021
• First Submitted That Met QC Criteria: November 17, 2021
• First Posted (Actual): November 18, 2021

Study Record Updates

• Last Update Posted (Actual): November 18, 2021
• Last Update Submitted That Met QC Criteria: November 17, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: pharmacokinetics; bioequivalence; Progesterone; generic drugs; Soft Capsule
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Progestins; Progesterone
• Other Study ID Numbers: FK/BE/PGIV/19

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No